Cargando…

Phase I Study and Clinical Pharmacological Evaluation of Daily Oral Etoposide Combined with Carboplatin in Patients with Lung Cancer

Twenty‐eight patients with inoperable or relapsed lung cancer were given a combination of oral etoposide, administered once a day at doses ranging from 40 to 60 mg/m(2)/day (d) for 21 consecutive days, and carboplatin, administered intravenously over 1 h at doses ranging from 300 to 400 mg/m(2) on d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ohune, Terumasa, Fujiwara, Yasuhiro, Sumiyoshi, Hidetaka, Yamaoka, Naoki, Yamakido, Michio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 1995
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920854/ https://www.ncbi.nlm.nih.gov/pubmed/7790322 http://dx.doi.org/10.1111/j.1349-7006.1995.tb03083.x

Ejemplares similares

A phase I and pharmacokinetic study of intraperitoneal carboplatin and etoposide.
por: McClay, E. F., et al.
Publicado: (1993)

No Alteration in DNA Topoisomerase I Gene Related to CPT‐11 Resistance in Human Lung Cancer
por: Ohashi, Nobuyuki, et al.
Publicado: (1996)

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.
por: Herben, V. M., et al.
Publicado: (1997)

Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer.
por: Matsui, K., et al.
Publicado: (1998)

Carboplatin/etoposide: Neutropenia and thrombocytopenia: case report
Publicado: (2021)

Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma
por: Franceschi, E, et al.
Publicado: (2004)

Prognostic Significance of p53 and ras Gene Abnormalities in Lung Adenocarcinoma Patients with Stage I Disease after Curative Resection
por: Isobe, Takeshi, et al.
Publicado: (1994)

A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS).
por: Warner, E., et al.
Publicado: (1998)

Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site
por: Piga, A, et al.
Publicado: (2004)

Paclitaxel-etoposide-carboplatin/cisplatin versus etoposide-carboplatin/cisplatin as first-line treatment for combined small-cell lung cancer: a retrospective analysis of 62 cases
por: Li, Yue-Ya, et al.
Publicado: (2015)

Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399
por: Gentzler, Ryan D, et al.
Publicado: (2023)

Enhancement of Tumor Radio‐response by Irinotecan in Human Lung Tumor Xenografts
por: Tamura, Kenji, et al.
Publicado: (1997)

Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis.
por: English, M. W., et al.
Publicado: (1996)

Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma
por: Imaya, Masayuki, et al.
Publicado: (2022)

Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL
por: Torka, Pallawi, et al.
Publicado: (2022)

Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide.
por: de Jong, R. S., et al.
Publicado: (1997)

Interstitial pneumonia following administration of pegfilgrastim during carboplatin and etoposide chemotherapy for small-cell lung cancer
por: Shirasawa, Masayuki, et al.
Publicado: (2016)

Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma
por: Mehrzad, Valiollah, et al.
Publicado: (2017)

Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report
por: Sokolova, Alexandra, et al.
Publicado: (2017)

Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer
por: Kataoka, Nobutaka, et al.
Publicado: (2020)

Treatment outcomes of T and natural‐killer/T‐cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy
por: Tay, Tricia, et al.
Publicado: (2022)

Gliosarcoma with Systemic Metastasis Showing Favorable Response to Ifosfamide, Carboplatin, and Etoposide Chemotherapy: An Autopsy Case Report
por: NAKAGAKI, Yuki, et al.
Publicado: (2022)

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
por: Reardon, D A, et al.
Publicado: (2009)

Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer/T-cell lymphoma
por: Tang, Tiffany, et al.
Publicado: (2020)

Retrospective Analysis of Bevacizumab in Combination with Ifosfamide, Carboplatin, and Etoposide in Patients with Second Recurrence of Glioblastoma
por: Arakawa, Yoshiki, et al.
Publicado: (2013)

Bortezomib, Ifosfamide, Carboplatin, and Etoposide in a Patient with HIV-Negative Relapsed Plasmablastic Lymphoma
por: Akce, Mehmet, et al.
Publicado: (2016)

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer
por: van der Burg, M E L, et al.
Publicado: (2002)

Remarkable response of recurrent endometrial adenocarcinoma to daily oral administration of half-dose etoposide
por: Nakamura, Yasuhiko, et al.
Publicado: (2018)

Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study
por: CAUBET, MATTHIEU, et al.
Publicado: (2015)

Carboplatin- and Etoposide-Loaded Lactoferrin Protein Nanoparticles for Targeting Cancer Stem Cells in Retinoblastoma In Vitro
por: Narayana, Revu V. L., et al.
Publicado: (2021)

Long-term complete response in small cell bladder carcinoma treated with carboplatin, etoposide, and atezolizumab
por: Kamitani, Rei, et al.
Publicado: (2022)

Comparison of Nutrition-Related Adverse Events and Clinical Outcomes Between ICE (Ifosfamide, Carboplatin, and Etoposide) and MCEC (Ranimustine, Carboplatin, Etoposide, and Cyclophosphamide) Therapies as Pretreatment for Autologous Peripheral Blood Stem Cell Transplantation in Patients with Malignant Lymphoma
por: Aoyama, Takashi, et al.
Publicado: (2018)

Differential Expression of DNA Topoisomerase IIα and IIβ Genes between Small Cell and Non‐small Cell Lung Cancer
por: Syahruddin, Elisna, et al.
Publicado: (1998)

Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702
por: Okamoto, H, et al.
Publicado: (2007)

Efficacy and safety of carboplatin and etoposide in older extensive‐stage small‐cell lung cancer patients with a poor performance status
por: Mamesaya, Nobuaki, et al.
Publicado: (2023)

Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers
por: Chon, Hye Sook, et al.
Publicado: (2017)

The Role of Glucuronidation in 7‐Ethyl‐10‐hydroxycamptothecin Resistance in vitro
por: Takahashi, Toshiaki, et al.
Publicado: (1997)

Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer
por: Ghielmini, M, et al.
Publicado: (1999)

Impact of dexamethasone, etoposide, ifosfamide and carboplatin as concurrent chemoradiotherapy agents for nasal natural killer/T-cell lymphoma
por: HATAYAMA, YOSHIOMI, et al.
Publicado: (2013)

Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent
por: Teicher, Beverly A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_d7etagpcueijr9cnafo963nmr8